For example, epidermal growth factor receptor (EGFR) inhibitors, such as gefitinib (market brand name, Iressa) and erlotinib (brand name, Tarceva)—which were both approved for the treatment of non-small cell lung cancer—are prime examples of this mutation-driven kinase inhibitor modification. This evidence concerns the gene EGFR and non-small cell lung carcinoma.